

**NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES
PREFERRED DRUG LIST REVIEW PANEL MEETING**

Tuesday, November 4, 2014

1:00pm – 5pm

**The State Library Building
109 E. Jones Street
Raleigh, NC 27601**

I. WELCOME AND INTRODUCTIONS

Jason Swartz, Pharmacy Program Manager opened the meeting at 1pm on November 4, 2014. He welcomed everyone to the annual NC Medicaid and Health Choice Preferred Drug List Review Panel meeting. Jason provided an overview of the procedures that would be followed during the meeting.

Jason stated that for each drug class review, if there are speakers registered to speak about a drug, time will be allowed for the speakers to share their comments before the panel members discuss and make recommendations about the drug class being discussed. The Speakers were to provide their name, affiliation and disclose any conflicts of interest. Speakers were to be mindful of the time limitations of this meeting and that the speaking time was to be limited to 3 minutes. Jason stated he would intervene at the end of 3 minutes and that this has to be done to ensure the meeting continues to move forward in a timely manner. Jason also stated that the panel has put into procedures that public comments received from pharmaceutical representatives shall be limited to new (within the past six months) information and shall be limited to comments on the superiority of their product when compared to the recommended preferred products along with supporting evidence. Next Jason stated that he would provide a brief summary of the comments received through the DMA website during the 45-day public comment period for each class and that the panel members received a copy of the public comments prior to the meeting. It was also mentioned that 15 comments for drug classes that are not on the agenda were received and according to the approved guidelines and procedures, these would not be discussed but the panel members had received them.

Jason then stated that he would provide a brief description of the proposed recommendations for each drug class. Panel members would then have an opportunity for discussion and then a vote of whether or not to approve the proposed decisions as presented or with changes. It was stated that panel members should recuse themselves from voting on a drug class if they have any conflicts of interests. Jason finished stating that he would not be voting on many classes on the PDL as his spouse works for the pharmaceutical industry and that as those classes came up he would recuse himself from voting.

Next the panel introduced themselves:

Chuck Rich, MD representing North Carolina Academy of Family Physicians
Paul Bush, Pharm.D, representing Hospital based Pharmacy
Holly Biola, MD, MPH, representing Community Care of North Carolina
Steve Wegner, MD, representing North Carolina Pediatric Society
Beit Steiner, MD, representing Medicaid Physicians Advisory Group
Jason Swartz, RPh, MBA, representing the Division of Medical Assistance
Burt Johnson, MD, representing North Carolina Psychiatric Association

Jonathan Weston, MD representing Old North State Medical Society

(arrived after introductions)

Andreas Maetzel, MD, PhD, representing Researched Based Pharmaceutical Companies

Bryon J. Hoffman, MD, representing North Carolina Chapter of the American College of Physicians

III. DRUG CLASS REVIEWS

1. ATYPICAL ANTIPSYCHOTICS (ORAL AND LONG ACTING INJECTABLES)

Jason staed that there were 17 speakers on this class. He then provided the following overview of what a PDL is:

“Before we begin, I want to clarify what the Preferred Drug List is and what it is not. The PDL is a way for DMA to say to prescribers “This a preferred, less costly drug, consider it first.” A non –preferred drug may or may not be more effective but is more costly. A PDL is not a formulary where some products are not covered, and for practical purposes unavailable. A PDL is not that. All products on the PDL are available either directly as a preferred product or through a prior authorization process if a non-preferred product is clinically needed.

The NC Medicaid PDL is not just what you see on paper or the website. Not all products available to prescribers in the market place are listed on the PDL. When a product class is not on the PDL it is deemed not reviewed and is considered preferred. For example, tri-cyclic antidepressants are not listed on the PDL. All are preferred.

Because Mental Health classes are new to the PDL, we will be instructing our Prior Authorization vendor to give leeway to PAs from providers who show that a patient has been stable on non-preferred product if/when that product moves to non-preferred. We will instruct our PA vendor to start accepting PAs for non-preferred product on December 1, 2014 to be in time for the January 1 implementation of the new PDL. That will give prescribers a full month to make requests to meet the needs of their patients.”

- Speakers:

Gerry Ackland	NAMI Advocate
Madeline Jaekle	NAMI Advocate
Robert James McHale M.D., M.Sc., FAPA	Medical Director, Monarch
Meghan Blankmann, PMHNP-BC	Nurse Practioner, Monarch
Mona Bhatti M.D	Fellowship Health Resources
Steven B. Worringham, MD	Medical Director, Psychiatrist, Carolina Outreach LLC
Robin B. Huffman	Executive Director, NC Psychiatric Association
Rohima Miah, MD	North Carolina Recovery Support Services
Laney Radke LPN	Port Human Services Outpatient clinic
Sally R. Cameron	Executive Director, NC Psychological Association & Foundation
Virginia Barney,RN, LCSW	Advance Behavioral Center
Robert A Millet MD	Private Practice
Kisha James, MD	Easter Seals UCP of NC/VA

Andrew J. Muzyk, Pharm.D.

Assistant Professor, Campbell University School of
Pharmacy; Clinical Specialist in Internal
Medicine/Psychiatry, Department of Pharmacy, Duke
University Hospital"
Otsuka America Pharma

Roderick Teat, PharmD

- There were 48 comments received for this drug class 19 of which cited the difficulties in finding the right drug or drug combination for patients and the added burden of prior authorization. 14 were general comments on antipsychotics and their use and the burden a PDL would cause, and 15 were comments on the need for Abilify Maintena to stay preferred.
- This is the first time this class will be managed. For Injectable Long Acting products, Abilify Maintena is proposed to move to non-preferred. For Oral Products, Brand Products of Clozaril, Fanapt Titration Pack, FazaClo, Geodon, Risperdal, Risperdal M, Seroquel, Versacloz, Zyprexa, Zyprexa Zydis will be made non-preferred and generic Symbyax will also be made non-preferred.
- Discussion occurred with some speakers in addition among the panel members a consensus was reached that the Panel should move Abilify Maintena to the preferred side and allow for trial and failure of only 1 preferred antipsychotic before a non-preferred antipsychotic could be used.
- A motion to approve the drug class with changes and a second were noted.
- Vote: TEN in favor; ZERO opposed

ANTIDEPRESSANTS (Other)

- Jason recused himself from voting
- No registered speakers for this drug class.
- There were no specific comments received for this drug class but the general mental health comments cited in the previous class could apply.
- This is the first time this class will be managed. We are moving new products Brintellix, Fetzima, Khdezla, Pristiq to non-preferred, old branded products Effexor XR, Remeron, and Wellbutrin to non-preferred leaving their generic equivalents preferred. New product Savella will be preferred.
- Discussion for this class centered on nefazadone and its preferred status now that there were liver concerns with the use of this medication. The Panel chose to move this product to non-preferred status.
- A motion to approve the drug class with changes and a second were noted.
- Vote: NINE in favor; ZERO opposed

ANTIDEPRESSANTS (SSRI)

- No registered speakers for this drug class.
- There were no specific comments received for this drug class but the general mental health comments cited in the previous class could apply.
- This is the first time this class will be managed. We are moving mostly old branded product to non-preferred leaving their generic equivalents as non-preferred. The exception is that no long acting product will be preferred.
- Dr Johnson stated he had no concerns with no long acting SSRI being preferred
- A motion to approve the drug class as proposed and a second were noted.
- Vote: TEN in favor; ZERO opposed

ANTIHYPERKINESIS

- No registered speakers for this drug class.
- There were 1 comments received for this drug class for Intuniv.
- This is the first time this class will be managed. Brand Concerta, Intuniv, Methylin Chewable Tablets, ProCentra, Ritalin SR, Zenzedi are moving to non-preferred, while generic products that are costly to the state, including generic Focalin, Focalin XR, Dexadrine Spantules, ProCentra, Desoxyn, Metadate CD, Ritalin LA, and Methylin Solution will also be made non-preferred.
- There was discussion on Intuniv and that it could stay non-preferred as it would not be first line therapy and the panel agreed.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: TEN in favor; ZERO opposed

HEPATITIS C AGENTS

- One registered speakers for this drug class.
Ray E Lancaster, BS, PharmD, Director, Medical Science, Gilead – Speaking on Sovaldi
- No comments were received during the public comment period.
- New brand products, Sovaldi and Olysio are being added to non-preferred
- Discussion between the Panel and Dr. Lancaster on the cost of Sovaldi, and future competition occurred.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed; Dr. Biola recused herself as her spouse works for Gilead.

ACE INHIBITORS

- There is one registered speaker
Susan Lindsey, VGA Associates, speaking on Epaned
- No comments were received during the public comment period.
- We are adding new branded liquid Epaned and previously never listed brand Aceon to the non-preferred side in addition to moving low utilized at 1.4% or less costly generics foxinopril, moexipril, perindopril, quinapril, and trandolapril to non-preferred. (1.4% = quinapril)
- Discussion occurred about enalapril and lisinopril being compounded at a much less cost than Epaned, thus Epaned is not more advantageous.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: TEN in favor; ZERO opposed

ORAL PULMINARY HYPERTENTION

- There is 1 registered speakers for this drug class.
Sonja Grooms-Smith, PhD, Actelion Pharmaceuticals will be speaking on Opsumit
- No comments were received during the public comment period.
- Proposal is to move Brand Adcirca to non-preferred and new products Adempas, Opsumit, and Orenitram ER to non-preferred.
- Discussion occurred about Opsumit and how it was better than proposed preferred products. No comparison studies exist. Safety was questioned, but was clarified by Dr. Grooms-Smith.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: TEN in favor; ZERO opposed

MULTIPLE SCLEROSIS AGENTS

- There is 1 speakers registered for this drug class:
 1. Melinda Merrill, Ph.D., Biogen Idec speaking on Tecfidera
- There were no comments received during the public comment period.
- The changes include moving Extavia to the preferred side and Betaseron to the non-preferred side. New product Rebif Rebidose Pen Injector is proposed as preferred.
- Discussion on how Tecfidera is better – Dr. Merrill stated flu like symptoms on betaseron products and they are injectable where Tecfidera is oral. Distinct safety advantages studies cited by Dr. Merrill. Panel felt this is a chronic disease and that patient can have access to Tecfidera through a prior authorization or trial and failure of preferred product.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: TEN in favor; ZERO opposed

ULCERATIVE COLITIS AGENTS (oral)

- We have 1 registered speaker for this drug class.
Matthew M. Goodwin, PharmD, Salix Pharmaceuticals is speaking on Uceris Tablets
- No comments were received during the public comment period.
- The recommendation for the oral products is to mover brand Pentasa to the non-preferred side and add new brand product Uceris to the non-preferred side.
- Discussion on direct comparison studies and there are none.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: TEN in favor; ZERO opposed

INTRANASAL RHINITIS AGENTS

- Jason recused himself from voting
- There is one registered speaker:
 1. Tyson S. Park, PharmD , Teva Pharmaceuticals (QNasl)
- There were no comments received during the public comment period
- The recommendations include moving brand Nasacort Rx to non-preferred and generic Nasalide, flunisolone to non-preferred.
- There was no discussion.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

OPIOID DEPENDENCE

- There is one registered speaker for this class
Richard Gustin, Ph.D. Orexo US, Inc is speaking on Zubsolv
- There was 1 comment received during the public comment period on Zubsolv.
- The recommendation is to move generic suboxone tablets to preferred and place new products Evzio and Zubsolv as non-preferred.
- Discussion on how Zubsolv saved money because it you see less diversion and how it is safer for children due to better packaging. Questions arose about pricing between Suboxone and Zubsolv since they are essentially equivalent.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed; ONE abstain

Dr. Steven Wegner left the meeting

IMMUNOMODULATORS

- There are 2 registered speakers for this class
 1. Carolina M. Lowe, PharmD, Celgene Corporation Speaking on Otezla
 2. Vanessa Castellano, Ph.D., Pfizer, Speaking on Xeljanz
- There was three comment received for this drug class requesting Xeljanz to be preferred.
- The recommendation includes adding the new to market brand Actemra, Entyvio and Otezla to the non-preferred side.
- Discussion on Otezla as being equal to and not superior to the preferred products. Discussion on how Xeljanz works differently.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

A fifteen minute break occurred.

ALZHEIMER'S AGENTS

- No registered speakers for this drug class.
- There were no comments received for this drug class.
- New generic Aricept 23mg Tablet is non-preferred status while generic orally disintegrating Aricept is moving to preferred status. Namenda Tablet Dose Pack is moving to non-preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

LONG ACTING NARCOTIC ANALGESICS

- There are no speakers registered for this drug class:
- There were three comments requesting brand product Butrans to be preferred
- Embeda is being removed as it is no longer made. Generic Avinza is to be non-preferred in addition to new drugs Xartemis XR, and Zohydro.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SHORT ACTING SCHEDULE II NARCOTIC ANALGESICS

- No registered speakers for this drug class.
- There were no comments
- Hydrocodone products are now included in this class and have no changes from when they were C3 products. The main changes are the movement of oxycodone capsules and oxycodone concentrated solution moving to preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SCHEDULE III-IV NARCOTIC ANALGESIC COMBINATIONS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- Tramadol products have been moved to this class there are no changes for tramadol containing medications. The only change is generic Talacen is moving to non-preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

NSAIDs

- No registered speakers for this drug class.
- There was no comments on this class
- New product Zorvolex is non-preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SECOND GENERATION ANTICONVULSANTS

- Jason recused himself from voting
- No registered speakers for this drug class.
- There were no comments on this class
- Changes include moving generic lamotrigine kit moving to preferred. New products Aptiom, Fycompa, Qudexy, and Trokendi XR are non-preferred. Remember that all medications when a diagnosis of epilepsy is presented at POS are covered without prior authorization.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

CEPHALOSPORINS AND RELATED ANTIBIOTICS

- Jason recused himself from voting
- No registered speakers for this class.
- No comments were received during the public comment period.
- Brand Suprax chewable tablets and capsules have been added to the preferred side as Suprax tablets have been discontinued, but until they are no longer in the drug file will be moved to the non-preferred side. In addition, generic Cedax is non-preferred high cost generic.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

MACROLIDES AND KEOTLIDES

- This class was not open. This was a technical change. Generic EES is being removed as it is no longer made

NITROMIDAZOLE ANTIBIOTICS

- There no speakers for this class
- No comments were received during the public comment period.
- Vancocin is moving to non-preferred status while its generic will be preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ORAL TETRACYCLINES

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- Generic Monodox (doxycycline monohydrate) will be preferred while previously unlisted brands Minocin and Monodox will be listed as non-peferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ORAL ANTIFUNGALS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- Generic ketoconazole will be moving to non-preferred due to recent clinical limitations on its use while generic clotimazole troche will be made preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

HEPATITIS B AGENTS

- Jason recused himself from voting
- No registered speakers for this drug class.
- No comments were received during the public comment period.
- New costly to the state generics of Epivir HBV and Hepsera are being added to non-preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

ACE INHIBITOR CALCIUM CHANNEL BLOCKER COMBINATIONS

- No registered speakers for this class.
- No comments were received during the public comment period.
- We are moving brand Lotrel to non-preferred. Its generic will stay preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ACE INHIBITORS DIURETIC COMBINATIONS

- There are no registered speakers
- No comments were received during the public comment period.
- Proposed moving high cost low utilized at less than 0.09% or less hydrochlorothized combination products of fosinopril, moexipril, and quinapril.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ANGIOTENSIN II RECEPTOR BLOCKER

- No registered speakers for this class.
- No comments were received during the public comment period.
- Proposed adding new high cost generic Micardis to non-preferred. The brand is also non-preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ANGIOTENSIN II RECEPTOR BLOCKER COMBINATIONS

- No registered speakers for this class.
- No comments were received during the public comment period.
- Proposed to add new high cost generic Twynsta to non-preferred side. The brand is also non-preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ANTI-ARRHYTHMICS

- This class was not open. There was a technical change with Tambacor brand product being removed as it is no longer made

BETA BLOCKERS

- Jason recused himself from voting
- No registered speakers for this class.
- There was no comment received during the public comment period.
- The proposal is to move generic move low utilized at 0.8% or less high cost generics to the non-preferred side. Those products are betaxolol, bisoprolol, pindolol, timolol.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: Eight in favor; ZERO opposed

BETA BLOCKERS DIURETIC COMBINATIONS

- No registered speakers for this class
- There was no comment received during the public comment period.
- The proposal is to move generic move low utilized at 0.09% or less high cost generics to the non-preferred side. Those products are brand Corzide, generic Corzide and brand Tenoretic.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

BILE ACID SEQUESTRANTS

- No registered speakers for this class
- There was no comment received during the public comment period.
- The proposal is to brand products Colestid, Questran and Questran Light to non-preferred, keeping their generic equivalents preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

CORNOARY VASODIALTORS

- No registered speakers for this class.
- There were no comments received during the public comment period.
- Proposal is to add previously unlisted brand Nitro-Dur to the non-preferred side and remove IsoDintrate listing as it is no longer made.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

NIACIN DEIVATIVES

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- Proposal move brand Simcor to non-preferred (utilization less 0.09%) and move new high cost generic for Niaspan to non-preferred leaving brand preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposal to move all generic Cardizem CD, Cardizem SR, and Tiazac products to preferred, and moving generic Verelan PM to non-preferred leaving the brand preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

PLATELET INHIBITORS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposal to move brand Effient to preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SYMPATHOLYTICS AND COMBINATIONS

- No registered speakers for this drug class.
- No comments were received for this drug class.
- The proposal is to move Brand Catapres Tablet, Clorpres and Tenex to the non-preferred side, (utilization less than 0.09%) and move higher cost generic methyldopa/HCTZ combo, methyldopate injection and reserpine to non-preferred (Utilization less than 0.09%)
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TRIGLYCERIDE LOWERING AGENTS

- Jason recused himself from voting
- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposed change is move brand Tricor and Trilipix to the non-preferred side leaving only gemfibrozil as preferred
- The panel discussed being okay with allowing the trial and failure of only gemfibrozil
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

ANTIMIGRAINE AGENTS

- Jason recused himself from voting
- No registered speakers for this class.
- No comments were received during the public comment period.
- The proposed changes to this drug class is to move generic Maxalt MLT to the preferred side
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

ANTINARCOLEPSY

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The changes recommended for this drug class are to move brand Provigil to preferred leaving its generic and brand Nuvigil non-preferred. Only Provigil will be preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ANTIPARKINSON AND RESTLESS LEG SYNDROME AGENTS

- Jason recused himself from voting
- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The changes recommended for this drug class adding two new brand products, Eldepryl and Ldosyn to the non-preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

INSULIN PRODUCTS – LONG ACTING

- There are no speakers registered
- Levimer Pen, cited on the posted PDL as Flexpen and will be listed as FlexTouch will move to preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ALPHA-GLUCOSIDASE INHIBITORS

- There are no speakers for this class
- There were no comments received for this drug class.
- The proposed changes include moving brand Precose to non-preferred keeping its generic equivalent preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

BIGUANIDES AND COMBINATIONS

- There are no speakers for this class
- There were no comments received for this drug class.
- The proposed changes include moving generic Fortamet, metform ER not equivalent to Glucophage ER to non-preferred as it is a costly generic. Both Fortamet and its generic will be non-preferred. (utilization is 0.1% or 120 scripts per month)
- There was discussion as to what would happen if a prescriber writes for metformin ER. It was answered that it depended on what strength they wrote for because Fortamet ER had different strengths than Glucophage ER and that the prescriber would get a call from the pharmacy if they wrote for the Fortamet ER strength.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

MEGLITINIDES

- There are no speakers for this class
- There were no comments received for this drug class
- The proposal is to move the new expensive generic Prandin to the non-preferred side, keeping the brand Prandin preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR

- There are no speakers for this class
- No comments were received during the public comment period.
- The recommendation adds new to market brand Farxiga to the non-preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ANTIEMETIC-ANTIVERTIGO AGENTS (recuse)

- There are no speakers registered
- No comments were received during the public comment period.
- The proposed change is to move brand Marinol to the non- preferred side and add new product Zuplenz and previously unlisted product Compazine Rectal Suppositories to the non-preferred side. Previously unlisted generic Tigan, trimethobenzimide will be added to the preferred side.
- There was a discussion on where the generic Marinol was placed and it was answered on the non-preferred side with its brand.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

BILE ACID SALTS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposed change includes moving brand Actigall, Urso, Urso Forte and the generic for Urson and Urso Forte to the non-preferred side leaving only generic Actigall capsules, urisodiol, as preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

H. PYLORI COMBINATIONS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The recommendation adds Pylera to the preferred side and the new expensive generic PrevPac to the non-preferred side, leaving brand PrevPac preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

PROTON PUMP INHIBITORS

- No registered speakers for this class.
- No comments were received during the public comment period.
- The recommendation includes moving generic OTC Prevacid and Prilosec to the non-preferred side, adding new generic Nexium, and Nexium OTC to the non-preferred side, adding new generic Prilosec Suspension and new generic Aciphex to the non-preferred side. Previously unlisted brand Protonix Suspension will be listed as preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SELECTIVE CONSTIPATION AGENTS

- There are no speakers registered for this drug class:
- There were no comments received during the public comment period
- The recommendation is to move brand Linzess to the preferred side adding previous unlisted brand Lotronex to the non-preferred side
- There was a discussion as to why we had an exemption for males on the non-preferred side and why it was being removed. It was explained that the only non-preferred last year Linzess and because Amitiza, the preferred product, was only for females, an exemption was made for males for Linzess. Since Linzess is moving to preferred, there was no need for the exemption anymore.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ULCERATIVE COLITIS AGENTS - Rectal

- There are no speakers registered
- No comments were received during the public comment period.
- The recommendation for the is to move the brand and generic Rowasa Kit, brand Rowasa Enema, and Brand SFRowasa to the non-preferred side, leaving generic Rowasa enema and brand Canasa Suppository as preferred product.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

BENIGN PROSTATIC HYPERPLASIA TREATMENTS (recuse)

- Jason recused himself from voting
- There are no speakers registered
- There were no comments received during the public comment period.
- The proposal is to move generic Uroxatral to preferred and brand Proscar and Uroxatrol to non-preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

ELECTROLYTE DEPELTERS

- There are no speakers registered
- There were no comments received during the public comment period.
- The proposal is to move brand Renvela (38.1% utilization – 110/month) to non-preferred and adding new brand Velphoro to non-preferred
- There was a discussion on the movement of high utilization product and if the cost savings was worth it and it was noted that it was.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

URINARY ANTISPASMODICS

- There were no speakers registered
- There were no comments received during the public comment period.
- The recommendation is to move cancel all moves that were going to happen on November 17th and only add the new generic of Detrol LA to the non-preferred side. Both the brand and generic Detrol LA will be non-preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ORAL ANTICOAGULANTS

- There are no speakers registered to speak on this class
- There was 1 comment received during the public comment period requesting Eliquis to be preferred.
- The recommendation is to add brand Eliquis to the preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

OPHTHALMIC ALLERGIC CONJUNCTIVITIS AGENTS

- This class was not open as this was a technical change with the removal of brand Alamast as it is no longer made

OPHTHALMIC ANTIBIOTICS

- No registered speakers for this drug class
- No comments were received during the public comment period.
- The proposed changes are adding new expensive generic Zymaxid, gatifloxacin to the non-preferred side and adding previously unlisted product brand Ilotycin to the non-preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS

- No registered speakers for this drug class
- No comments were received during the public comment period.
- The proposal is to move generic Neo Polycin HC, Cortisporin, and Vasocidin to the non-preferred side leaving generic Maxitrol, brand Tobradex Ointment and Suspension as preferred. (Utilization is 5% for generic Cortisporin and less than 0.5% for the others.)
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

OPHTHALMIC –GLAUCOMA – ALPHA 2 ADRENERGIC AGENTS

- No registered speakers for this class.
- There was 1 comment received during the public comment period. The provider request that apraclonidine stay preferred as an alternative to brimonidine.
- The recommendations to move apraclonidine to non-preferred leaving Alphagan P and generic Alphagan, brimonidine as preferred.
- There was discussion on the comment and it was decided that the provider could request through the PA process if an allergy develops.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

OPHTHALMIC –GLAUCOMA – BETABLOCKER AGENTS

- This class was not open as this was a technical change as Optipranolol is being removed as it is no longer made

BONE RESORPTION SUPPRESSION AGENTS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The recommendation is to move brand Miacalcin and its generic calcitonin nasal to non-preferred, leaving only brand Fortical as the preferred calcitonin product. In addition brand Dirdronel is being removed from the list as it is no longer made and new to market generic Evista will be added as preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

OTIC ANTI-INFECTIVES AND ANESTHETICS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- This class was not part of the original PDL presented to the P&T and therefore should not be open. I want to recommend that we keep this class as is with no changes
- There was no discussion
- A motion to approve the drug class without changing anything with a second was noted.
- Vote: NINE in favor; ZERO opposed

BETA ADRENERGIC HANDHELD, SHORT ACTING AND NEBULIZER AGENTS

- This class was not open as this was a technical change because in the handheld class, Relion Ventolin HFA is no longer made and being removed and in the nebulizer class, brand Accuneb is no longer made and being removed.

COPD AGENTS

- There are no registered speakers
- No comments were received during the public comment period.
- The recommendation is to move brand Duoneb to the preferred side.
- There was discussion on why move brand to the preferred side with its generic and if Duoneb is even made anymore.
- A motion to approve the drug class as proposed and a second were noted
- Vote: NINE in favor; ZERO opposed

CORTICOSTEROIDS

- Jason recused himself from voting
- There are no registered speakers
- There were no comments received during the public comment period
- The recommendations is adding new brand product Aerospan to the non-preferred side
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

CORTICOSTEROID COMBINATIONS

- Jason recused himself from voting
- There are no registered speakers
- There were no comments received during the public comment period
- The recommendations is to add new brand product Breo Elipta to the non-preferred side
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

LEUKOTRIENE MODIFIERS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposal is to move brand Singular Granules to non-preferred and generic Singular Granules to preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

LOW SEDATING ANTIHISTAMINES

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The recommendations include moving brand Claritin OTC Solution to preferred while removing fexofenadine generic Allegra RX from the non-preferred side as they are no longer made. In addition adding a specifically labeled cetirizine OTC solution (5mg/5ml) as it is very costly and adding the new generic Zyrtec OTC to the non-preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

LOW SEDATING ANTIHISTAMINE COMBINATIONS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposal is to make all products except generic Claritin D OTC non-preferred. The quantity limit remains the same.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL ACNE AGENTS

- Jason recused himself from voting
- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The changes recommended moving clindamycin phosphate gel, lotion and plegets to preferred and moving erythromycin gel, solution and Retin-A Micro Gel to the non-preferred side. New products added to the non-preferred side include branded products Benzefoam, Benzefoam Ultra, BP Wash, Fabior, SSS10-4 and a previously unlisted generic sufacetamide sodium cleanser. 3 products no longer made and being removed are a generic sufacetamide/urea combination, sulfacetamide/avobenzene/sulfur combination, and branded TL Triseb.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

TOPICAL ANDROGENIC AGENTS

- No registered speakers for this drug class.
- No comments were received for during the public comment period.
- The change to this drug class is moving Testim to the preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL ANESTHETICS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The change to this drug class is to add the new generic Lidoderm patch to the non-preferred side where the brand Lidoderm is currently placed.
- There was discussion on how to get Lidoderm product and it was explained that a PA would be required because there is clinical criteria.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL ANTIBIOTICS

- Jason recused himself from voting
- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The change to this drug class is to move brand Bactroban Cream to the preferred side, keeping the generic non-preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

VAGINAL ANTIBIOTICS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposal is to move brand Cleocin Vaginal Cream and generic Cleocin Vaginal cream to the non-preferred side and adding previously unlisted brand product Clindese to the non-preferred side.
- There was a question about Metrogel status and it was noted that it was staying preferred.
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL ANTIFUNGALS

- No registered speakers for this class.
- No comments were received during the public comment period.
- Proposal is to remove brand Bensal HP as it is no longer made and add new product Luzu to the non-preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL ANTIPARASITICS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The recommendation is to move brand products Natroba and Sklice to the preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL ANTIVIRALS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The recommendations moves brand Zovirax cream to the preferred side.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL IMMUNOMODULATORS – ATOPIC DERMATITIS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The recommendations moves brand Protopic to the non-preferred side leaving Elidel as preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL IMMUNOMODULATORS – IMIDAZOQUINOLINAMINES

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- This is a new class making brand Aldara the preferred product and its generic non-preferred along with a brand Zyclara which is the same medication in a lower strength.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

TOPICAL PSORIASIS AGENTS

- Jason recused himself from voting
- No registered speakers for this class.
- No comments were received during the public comment period.
- The recommendations include moving generic Dovenex Cream to preferred and the brand Dovenex Cream to non-preferred. Brand Dovonex Solution is being removed from the PDL as it is no longer made.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: EIGHT in favor; ZERO opposed

TOPICAL STEROIDS

- No registered speakers for this class.
- No comments were received during the public comment period.
- Proposed changes are occurring in the medium potency and the high potency classes. In the medium potency class the movement of fluticasone generic for Cutivate to preferred and the removal of brand Westcort as it is no longer made. For the high potency class the movement of triamcinolone acetonide, generic Kenalog lotion to preferred, making all triamcinolone acetinonide formulations preferred moving bethamethasone valerate ointment, generic for Valisone Ointment preferred. In addition, new product Trianex will be non-preferred. There is also a technical change in the very high potency class with Halac being removed as it is no longer made.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

EPINEPHRINE, SELF INJECTED

- No registered speakers for this class.
- No comments were received during the public comment period.
- This is a new class to the Preferred Drug List. The recommendation is to prefer brand Epi-Pen and Epi-Pen Jr. where 91.6% utilization is and non-preferring generic epinephrine, brand Auvi-Q, and Brand Adrenaclick
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ESTROGEN COMBINATION AGENTS

- No registered speakers for this class.
- No comments were received during the public comment period.
- This class was not presented to the P&T and should not have been posted with changes. I would like to recommend keeping this class as is with no changes.
- There was no discussion
- A motion to approve the drug class with no changes and a second were noted.
- Vote: NINE in favor; ZERO opposed

ESTROGEN ORAL/TRANSDERMAL AGENTS

- No registered speakers for this class.
- No comments were received during the public comment period.
- The recommendation is for brand Cenestin, Enjuvia, Evamist, Menest and Vivelle Dot to move to preferred and teh new product Duavee be non-preferred. Brand FemTrace is being removed as it is no longer made.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

ESTROGEN AGENTS, VAGINAL PREPARATIONS

- No registered speakers for this class.
- No comments were received during the public comment period.
- This is a new class to the PDL recommending Premarin Vaginal, Estrin, and Vagifem be preferred, (96% of utilization is here). Femring and Estrace Vaginal would be non-preferred
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

GLUCOCORTICOIDS, ORAL

- No registered speakers for this class.
- No comments were received during the public comment period.
- This is a new class to the PDL recommending used to maximize cost savings preferring product where 96.8% of utilization already is at.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

SKELETAL MUSCLE RELAXANTS

- This class was not open and this was a technical change only removing generic Norgesic Forte as it is no longer made

DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- The proposed change to this drug class is to add new brand oral solution Nymalize to non-preferred in addition to move the low utilized at 0.09% or less generic products of felodipine, isradipine, and nicardipine to the non-preferred side. Nifediac CC a branded generic and brand Cardene SR are being removed as they are no longer made.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

DIRECT RENIN INHIBITOR

- No registered speakers for this drug class.
- No comments were received during the public comment period.
- Proposal to move 2 higher cost brands, Amturnide and Tekamlo (utilization less than 0.09%) to non-preferred leaving Tekturna and Tekturna HCT as preferred.
- There was no discussion
- A motion to approve the drug class as proposed and a second were noted.
- Vote: NINE in favor; ZERO opposed

The meeting is adjourned at 4:40pm